Summary of findings for the main comparison. Interferon‐B‐1a versus placebo.
| Interferon‐B‐1a versus placebo | ||||||
| Patient or population: patients with active ulcerative colitis Settings: Outpatient Intervention: Interferon‐B‐1a versus placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | Interferon‐B‐1a versus placebo | |||||
| Improved IBDQ at week 8 | 406 per 10001 | 463 per 1000 (325 to 654) | RR 1.14 (0.80 to 1.61) | 194 (1 study) | ⊕⊕⊕⊝ moderate2 | Improvement > 15 points from baseline |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Control group risk estimates come from control arm of meta‐analysis, based on included trials. 2 Downgraded one level due to sparse data (86 events)